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Pheochromocytomas are rare neuroendocrine tumors. Although predominantly occurring in the adrenal
glands, these tumors can present anywhere along the sympathetic chain. Indeed, classical teaching states
that 10% of pheochromocytomas are extra-adrenal and 10% are malignant. We report a case of a 61-year-
old female who underwent presumptive cytoreductive nephrectomy and adrenalectomy for renal car-
cinoma but was instead found to have malignant pheochromocytoma. Proper identiﬁcation, surgical
extirpation, and follow-up are imperative for treatment. We review the classic and current literature
regarding management of this uncommon tumor.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction which revealed pancreatic and adrenal masses. Computed tomog-Pheochromocytomas are rare neuroendocrine tumors of the
chromafﬁn system. Although most chromafﬁn cells degenerate after
fetal life, residual cells reside within the adrenal medulla. However,
persistent extra-adrenal chromafﬁn tissue can exist anywhere along
the sympathetic chain. Classically, these catecholamine-secreting
tumors have been termed the “10% tumor,” in which 10% are ma-
lignant, 10% are bilateral, 10% are pediatric, 10% are familial, and 10%
are extra-adrenal. Familial causes include multiple endocrine
neoplasia type IIA, multiple endocrine neoplasia type IIB, von Hippel-
Lindau disease, and neuroﬁbromatosis type 1. Extra-adrenal pheo-
chromocytomas are also described as paragangliomas.
Malignancy in pheochromocytoma is difﬁcult to diagnose micro-
scopically. Therefore, malignant pheochromocytomas are diagnosed
by the presence of local invasion or metastatic disease. When met-
astatic, themost frequent locations are bone, lymph nodes, liver, lung,
and brain.
Case presentation
A 61-year-old female presented to her physician with episodic
abdominal pain. Her medical history was notable for hypertension
and a history of well-differentiated papillary breast adenocarcinoma
status 12 years after lumpectomy. An ultrasonogram was obtained,BY-NC-ND license (http://
4-367-5016.
. Figenshau).
Published by Elsevier Inc. All righraphy (CT) scan showed a 4.1-cm right adrenal mass, an 8.6  6 cm
enhancing left renal mass, and a 2-cm solid right pulmonary mass
(Fig. 1). Follow-up positron emission tomography and CT showed
ﬂudeoxyglucose uptake in all of these lesions. The presumptive
diagnosis of metastatic renal cell carcinoma (RCC) wasmade, and she
was taken to surgery for cytoreductive nephrectomy and contralat-
eral adrenalectomy. She had an uncomplicated surgery and recovery.
Final pathologic analysis revealed pheochromocytoma in both the
kidneys and the adrenal gland. Grossly, therewas a 7.4 6.8 6.5 cm
white renal mass with multifocal hemorrhage and necrosis. The ad-
renalmassmeasured 5.5 4.5 3.8 cm. Histologically, the tumorwas
comprised of neuroendocrine cells with a focally spindled appearance
arranged in small nests (Fig. 2). Lymphovascular invasion was iden-
tiﬁed. Immunohistochemical stains were performed and revealed the
tumor cells to be synaptophysin positive and chromogranin negative.
An S-100 immunostain highlighted sustentacular cells.
Postoperative metaiodobenzylguanidine (MIBG) scan was ob-
tained 6 weeks postoperatively. There was expected I-123 MIBG
activity in the salivary glands, myocardium, liver, and urinary
bladder (Fig. 3). The left adrenal gland demonstrated mild uptake of
I-123 MIBG thought to be hypertrophy. Images of the right lower
lobe pulmonary nodule showed no I-123MIBG activity but revealed
an increase in size. A subsequent resection of the pulmonary nodule
was diagnosed as metastatic breast cancer.Discussion
Pheochromocytomas are rare neuroendocrine tumors, with
a peak incidence between the third and ﬁfth decades of life.ts reserved.
Figure 1. Preoperative adrenal mass and contralateral pulmonary and renal masses.
Red arrows indicate the pulmonary, adrenal, and renal masses.
Figure 2. Characteristic polygonal nests of pheochromocytoma cells.
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are found to be hypertensive. Approximately 0.02%-0.5% of patients
are diagnosed with pheochromocytoma on hypertensive workup,
whereas 10% of pheochromocytomas are found incidentally.1
Malignant or metastatic pheochromocytoma is based on the
invasion of adjacent structures or the presence of multifocal dis-
ease. In a review of 550 nephrectomy specimens, 80 specimens had
concomitant adrenal lesions, of which 3 contained pheochromo-
cytomas.2 One renal specimen contained RCC, suggesting von
Hippel-Lindau disease as the etiology. The other 2 patients had
pheochromocytoma invading the kidney and oncocytoma. There
were no reports of multifocal pheochromocytoma.
The diagnosis of pheochromocytoma is often made by testing
urine catecholamines or plasma-free metanephrines. Plasma-free
metanephrines have a 96% diagnostic sensitivity and 85% diag-
nostic sensitivity for pheochromocytoma.3 If not already per-
formed, imaging is used for localization. Ninety-eight percent of
pheochromocytomas are located in the abdomen, and 90% areFigure 3. Postoperative computed tomography and metaiodfound within the adrenal medulla. Magnetic resonance imaging
(MRI) has been the imaging modality of choice, providing accurate
localization with contrast enhancement and without the use of
ionizing radiation. MIBG and CT imaging have historically provided
lower sensitivity for pheochromocytomas but still play a role in
staging and following these masses.
Histologically, pheochromocytomas are usuallywell-circumscribed
masses. Nests of polygonal or rounded cells, eponymously named
Zellballen, are characteristic. Features suggestive of aggressive tumor
growth include spindle morphology, increased mitotic rate, and inva-
sion of the organ’s capsule.
Radiographically, these tumors have characteristic high signal
intensity on T2-weighted MRI. Our patient did not receive this
initial MRI because the patient’s presentation and CT suggested
metastatic RCC. MIBG imaging is also used to identify and conﬁrm
metabolically active lesions. In patients receiving chemotherapy for
pheochromocytoma, MIBG shows utility in tracking response to
chemotherapy.4 A recent study of imaging ﬁndings in histologically
conﬁrmed pheochromocytomas showed that these tumors can
deviate from the classic presentation and appear heterogeneous or
have low signal intensity on T2 imaging. As a result, the authors
present another “10%” rule for negative activity on MIBG imaging.
Based on data from the Mayo clinic, 5-year survival for malig-
nant pheochromocytoma is 44%, compared with 96% for benign
tumors5 Survival is further decreased with the presence of pul-
monary metastases. Surveillance should include plasma-free orobenzylguanidine scan showing no activity in the lung.
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nephrines should be checked annually thereafter. Lifelong sur-
veillance is recommended. Most recurrences occur within 5 years,
but recurrences have been reported as long as 40 years from
original resection. Nonsurgical treatment includes high-dose
MIBG or chemotherapy comprising vincristine, dacarbazine, and
cyclophosphamide. Unfortunately, there have been no complete
responses reported and only 57% of cases experience a partial
response.
Conclusion
Malignant and metastatic pheochromocytoma is a rare neuro-
endocrine tumor. Although they have the same radiographic and
histologic characteristics of their benign counterpart, malignant
pheochromocytomas are diagnosed by the presence of multiple
tumors and offer a poorer prognosis. Treatment is typicallyextirpative surgery, although MIBG and chemotherapy have been
offered in nonsurgical cases.References
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